



Instructions:

- o All fields are mandatory for the request to be accepted. Indicate N/A where necessary, do not leave any fields blank.
- As this is a fillable PDF, please complete the form electronically. If handwritten forms are submitted, please write legibly.
- Refer to the Appendix for the list of Infectious Disease Markers tested at BMDP.
- Include the following documents with this request.
 - 1. Donor and Patient Laboratory HLA Typing.
 - 2. BMDP's DM-F-07 Transplant History Form For subsequent donations and MNCs requests.

| | | PATIE | NT DATA | | |
|-------------------|----------------------------|--------------------------|---------------------|---|----------------|
| BMDP Patient ID | | Patie | nt Registry ID | | |
| Patient Registry | | Tran | splant Centre | | |
| Patient Diagnosis | | Bloo | d Group/RhD | | |
| Sex | □м □F | Age | • | CMV | |
| Ethnicity | | Weight | (kg) | Weight Measurem (dd-mmm-y) | |
| | | | | | |
| | | DON | OR DATA | | |
| GRID | 3 7 8 5 | - | - (| - | - |
| Donor ID | | | | | |
| Sex | □м □F | Age | | Weight (kg) | |
| Ethnicity | | CMV | | Blood Group/RhD | |
| | | | | | |
| | | -COLLECTION | | | |
| | (Note: 5 | 60 ml is the maximu | n volume that car | i be requested) | |
| Are pre-col | lection samples r | equired? | Ť | | |
| 2. Shipping co | onditions | | | 2 - 8 °C <i>(Additional</i> lled Ambient | charges apply) |
| No anticoaç | gulant (ml) | AC | D (ml) | | EDTA (ml) |
| | | | | | |
| Additional Remark | KS (Please indicate if the | here is any extra testin | g required at worku | p in this section) | |
| | | | | · | |
| | tion sample ship | ping informatio | n | | |
| Attention/Nan | ne | | | | |
| Institution | | | | | |
| Address Line | 1 | | | | |
| Address Line | 2 | | | | |
| Telephone No | о. | | | | |
| Email Addres | is . | | | | |
| | | | | | |

Form number: DM-F-02 Effective Date: 23 Oct 2024

Version number: 2.0 Page: 1 of 7





| Donor ID | | | | | | | Pat | ient | : ID | | | | | | | | |
|----------|---|---|---|---|---|--|-----|------|------|--|--|---|--|--|---|--|--|
| GRID no. | 3 | 7 | 8 | 5 | 1 | | | | 1 | | | - | | | - | | |

| Contingency Plan | | | | | | | | | | | | | |
|--|-----------------|-----------------------------------|----------|---|-----------|--|--|--|--|--|--|--|--|
| To ensure the best possible outcome for transplant pa if the donor becomes unavailable to proceed with the could significantly impact the transplant process and the questions | e dona poter | ation. Please note, the abse | nce of a | continge | ency plan | | | | | | | | |
| 1. Are there other donors under consideration for this | patie | nt? | |] Yes | □ No | | | | | | | | |
| If yes, please indicate donor type: Please note that a backup donor may be requested from Bl workup concurrently as the primary donor, unless: i. There is uncertainty of primary donor's availability to do ii. It is confirmed that the primary donor is not proceeding applicable. | nate. with d | onation or G-CSF where | | Related E Primary N Backup N Others: | MUD | | | | | | | | |
| 2. If you have a backup MUD, is the backup donor in for this patient? | | | | | | | | | | | | | |
| 3. If you have answered yes to any of the above, is th the primary donor? If no, please explain below: | е ВМ | DP donor referenced above | е С |] Yes | □No | | | | | | | | |
| TDANOR | • • • • • | | | | | | | | | | | | |
| TRANSPLANT HISTORY 1. Has this nationt received any provious stem cell transplant? | | | | | | | | | | | | | |
| 1. Has this patient received any previous stem cell transplant? ☐ Yes ☐ No | | | | | | | | | | | | | |
| These questions shall only be answered in case of subsequent donation and please submit <u>BMDP DM-F-07 Transplant History form</u> to accompany this request: | | | | | | | | | | | | | |
| 2. Please list the source, types, and dates of any prev | lous | allogeneic) transplants. | | | | | | | | | | | |
| 3. Has the donor referenced above donated the stem | cells | to this patient before? | | Yes [| □ No | | | | | | | | |
| 3a. If yes, was any of the original stem cell product cr | yopre | served for later infusion? | ☐ Yes | □ No | □ N/A | | | | | | | | |
| 3b. If yes, was that product infused? Date of infusion: | | (DD/MMM/YYYY) | ☐ Yes | □ No | □ N/A | | | | | | | | |
| | | | | | | | | | | | | | |
| PREFERRED DATES | / PR | | | | | | | | | | | | |
| Preferred Collection Dates (in order of preference – DD/MMM/YYYY) | | Corresponding Planne (DD/MMM/) | | ion Date | ∌S | | | | | | | | |
| 1. | 1. | (DD/Mildini) | 1111) | | | | | | | | | | |
| 2. | 2. | | | | | | | | | | | | |
| 3. | 3. | | | | | | | | | | | | |
| Min. number of days prior to collection that donor o | eleara | nce must be received | | | | | | | | | | | |
| Total number of days of *Conditioning Regimen | | | | | | | | | | | | | |

*Conditioning Regimen is also known as Preparative Regimen. The number of days should include the start of the conditioning regimen to the day of stem cell transplant, including rest days.

E.g. The patient is admitted to the hospital on 01 Apr 2024, the conditioning regimen starts on 03 Apr 2024, and transplant is on 12 Apr 2024, there are a total of 10 days.

Form number: DM-F-02 Effective Date: 23 Oct 2024

Version number: 2.0 Page: 2 of 7





| Donor ID | | | | | | | I | Patie | ent IC |) | | | | | | | | | | | | | | |
|--|----------|---------|----------|--------------------|---------|----------|-------------------|-------------------|--------|-----------------|-------|--------|---------|-------------------|----------|-----|--|----|---|----|-----|-----|----------|--|
| GRID no. | 3 | 7 8 | 5 | - | | | | | - | | | | | | - | | | | | - | | | | |
| | | | | | | | | - ^- | | | 010 | | | | | | | | | | | | | |
| | | | | | | | ΕN | I CE | LL C | | | | | | | | | _ | | | | | | |
| Choice | | | | F | PBS | | | | | | Bor | | Marr | rov | V | | | Ly | m | | ocy | yte |) | |
| 1 st | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 nd | | | | | | <u> </u> | | | | | | |] | | | | | | | | | | | |
| | | | | COLLECTION DETAILS | | | | | | | | | | | | | | | | | | | | |
| Due do et To | | | | | | | | eresi | | | | | C, M | ları | ow. | , | | | | | | 4 | | |
| Product Ty | | | | | | 2-5 x | 10 ⁶ (| CD34 ⁴ | | | (1 | imit 2 | 2 x 10 | 1T ⁸ (| NC/k | g) | | | _ | | hoc | _ | e | |
| Cell Type | е | | | | | CE |)34· | + | | | | | TN | IC | | | | | | CD |)3+ | | | |
| Required Cel | lls/kg | | | | | | | | | | | | | | | | | | | | | | | |
| Patient Weigh | | | | | | | | | | | | | | | | | | | | | | | | |
| Total number of (required cells x pate) | | - | t) | | | | | | | | | | | | | | | | | | | | | |
| Cells for quality a | | | - | | | | | | | | | | | | | | | | | | | | | |
| testing | 4 | (90) | | | | | | | | | | | | | | | | | | | | | | |
| Transport Temper | rature | (°C) | | | | | | | | - | | | | | | | | | | | | | | |
| Additional instructi | ione (i | if any | , | | | | | | | | | | | | | | | | | | | | | |
| Additional instructi | 0113 (1 | ii aiiy | ' | | | | | | | | | | | | | | | | | | | | | |
| PBSC Collection (Me | edical e | xplana | tion f | or r | eque | esting | moi | re thai | 15X | 10 ⁶ | CD3 | 4+/kg | g patie | ent ı | veig | ht) | | | | | | | | |
| | | • | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| (BMDP USE ONLY) Me | edical | Docto | or-on | ı-C | all C | omi | men | nts: | | | | | | | | | | | | | | | | |
| (2.11.21.7.11.7.11.17.17 | Januar | | | . • | <u></u> | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | - 2 | | | | | | | | | | | | | |
| Marrow Collection (| Medical | explai | natior | n fo | r req | uesti | ng m | nore th | nan 2 | X 10 | O° TN | IC/kg | g patie | ent v | veig | ht) | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| (BMDP USE ONLY) Me | edical | Docto | r-on | ı-C | all C | omi | men | nts: | | | | | | | | | | | | | | | | |
| , | | | | | | | | | | | | | | | | | | | | | | | | |

Form number: DM-F-02
Version number: 2.0

Effective Date: 23 Oct 2024
Page: 3 of 7



| Donor ID | | | | | | | | Pati | ent l | D | | | | | | | | | | | | | |
|---|-------|------|-------|--------------------|------|-------|-----|-------|--------|---------------------|--------------|------|-------|-------|---------------------|------|------|-------|-----|----|---------------|----|--|
| GRID no. | 3 | 7 | 8 | 5 | - | | | | | - | | | | | - | | | | | - | | | |
| | | | | | | | | 1 | | | | | | | | | 1 | | _ | | | | |
| | | | (No | ote: 5 | i0ml | | | | | | CTIC that | | | requ | estec | d) | | | | | | | |
| Are additiona | l saı | mple | | | | | | | | | | | | • | | • | |] Ye | s | | □ 1 | ۷o | |
| 2. Is Donor plas | ma | requ | uirec | 1? | | | | | | | | | | | | | E |] Ye | s | | □ 1 | Vo | |
| If yes, please indicate fi | | | | | | | | | | | | | | | | | ı | | | | | | |
| (Note: max of 100ml plas | ma p | er d | onati | ion d | ay c | an be | rec | quest | ed. 2 | 00ml | per da | y fo | or cı | ryop | reser | ved | pro | duct) | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | _ | |
| Indicate the amount | and | d ty | ре о | f tuk | | _ | | | | he T | ransı | ola | nt C | Cent | tre: | | | | | | | | |
| | | | | Day | | riph | era | I BI | | 21/ 2 | | | | | Day | 1 | Р | rod | uct | |) ov 2 | | |
| | | (1 | marro | Day w an | | BSC) | | | (Pl | ay 2 BSC) | | | (n | narro | Day w and | d PE | BSC) | | | (F | Day 2 PBSC |) | |
| No anticoagulant (m | l) | | | | | | | | | | | | | | | | | Ų | | | | | |
| ACD (ml) | | | | | | | | | | | | | | | | | | | | | | | |
| EDTA (ml) | | | | | | | | | | | | | | | | | | | | | | | |
| Additional blood | | | | | | | • | | nal ci | harge | es app | ly) | | | | | | | | | | | |
| temperature | | | | | | | | | | | | | | | | | | | | | | | |
| Additional Remarks | | | | | | | | | _ | | | _ | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | PR | OD | UCT | TF | RAN | ISF | OR | T / I | DEL | IVER | RΥ | INF | OF | RMA | TI | ON | | | | | | |
| Attention/Name: | | | | | | | | | | | | | | | | | | | | | | | |
| Contact Number: | | | | | | | | | | | | | | | | | | | | | | | |
| Fax Number: | | | 7 | | | | | | | | | | | | | | | | | | | | |
| Email: | | | | | | | | | | | | | | | | | | | | | | | |
| Facility: | | | | | | | | | | | | | | | | | | | | | | | |
| Address: | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Country: | | | | | | | | | | | Ро | sta | I/Zi | рC | ode | : | | | | | | | |
| Emergency contac | t | | | | | | | | | | | | | | | | | | | | | | |
| (Name and person mus different from the main contact above) | | | | | | | | | | | | | | | | | | | | | | | |

Form number: DM-F-02
Version number: 2.0

Effective Date: 23 Oct 2024
Page: 4 of 7



| Donor ID | | | | | | | | Pati | ent | ID | | | | | | | |
|----------|---|---|---|---|---|--|--|------|-----|----|--|---|--|--|---|--|--|
| GRID no. | 3 | 7 | 8 | 5 | - | | | - | | | | _ | | | - | | |

DISCLAIMER:

The BMDP <u>will not</u> initiate a second day collection if the number of cells collected on day one has reached 3×10^6 /kg patient weight unless an amount greater than 5×10^6 /kg patient weight is requested and approved by BMDP medical subcommittee

The cell products collected from the donor are intended solely for the purpose of immediate therapeutic treatment of the abovementioned patient unless planned cryopreservation prior to initial infusion to the patient is approved in advance by BMDP's medical chairperson.

For cryopreservation request that is approved by BMDP's medical chairperson, BMDP shall initiate a second day collection if the number of cells collected on day one is less than 5 x 10⁶ CD34+ cells/kg patient weight unless an amount less than 5 x 10⁶ CD34+ cells/kg patient weight is requested.

Items that were loaned from CC for cryopreservation such as cassettes and cryobox must be returned within a month after donation date or additional charges may be imposed.

Excess cells may be stored for future therapeutic treatment of the patient. No other uses of these cells are permissible Cells not used for the therapeutic treatment of the above-mentioned patient must be disposed of according to internal procedures and details provided to BMDP.

BMDP must be provided detailed information concerning the use and/or disposal of all portions of this cell product. Deviations from these terms are not permitted without written prior approval from BMDP.

Any serious product events and/or adverse reactions must be reported to the BMDP within 24 hours of occurrence and thereafter a SEAR/SPEAR report must be completed and submitted to the WMDA office by the BMDP.

As per WMDA Standards 6.04.3 "HLA verification typing results of the potential recipient should be available prior to requesting a specific donor for workup. At the latest, results must be available before the donor begins mobilisation or proceeds to collection, or the patient begins with the preparative regimen, whichever is earliest." Please ensure the patient's confirmatory/verification typing result is available to the search registry for this donation request.

| Regarding the donor designated abwith stem cell collection for above | | formation is acceptable to proceed |
|--|--------------------|------------------------------------|
| | | |
| Form Completed By | Date (DD/MMM/YYYY) | Transplant Physician Signature |

| | FOR <u>BMDP</u> OFFICIAL USE ONLY | | | | | | | | | | |
|--|---|----------------------------------|--|--|--|--|--|--|--|--|--|
| BMDP Medical Panel Doctor-on-ca exceeding the above-mentioned li | II's signature is required for approva mits. | als of any request for cell dose | | | | | | | | | |
| | | | | | | | | | | | |
| Name of Doctor-on-call | Date (DD/MMM/YYYY) | Doctor-on-call Signature | | | | | | | | | |

Form number: DM-F-02 Effective Date: 23 Oct 2024

Version number: 2.0 Page: 5 of 7



Appendix: Infectious Disease Markers

The following is the list of standard infectious disease markers that will be performed at BMDP Workup. If you require any additional tests not in this list to be done at workup, please indicate under "Additional Remarks" of the BMDP Workup Request and Prescription form. BMDP will inform you on the turn-around time and the additional charges that will apply. If additional test requested cannot be performed, precollection blood samples up to 50ml can be collected from the donor and samples will be shipped to TC. Donors will also be tested for local diseases that are important to consider in HSC transplants. Donors who have recently traveled abroad shall also assessed for infectious diseases prevalent in those travel regions.

- a. Hepatitis B Virus (HBsAg, Anti-HBc, Anti-HBs, NAT HBV)
- b. Hepatitis C Virus (Anti-HCV, NAT HCV)
- c. Human T-Lymphotropic Virus (Anti-HTLV I, Anti-HTLV II)
- d. Human Immunodeficiency Virus (Anti-HIV1 and 2, NAT HIV)
- e. Syphilis (Syphilis TP Ab)
- f. Cytomegalovirus (CMV IgG, CMV IgM)
- g. Herpes Simplex Virus (HSV type I IgG, HSV type II IgG)
- h. Varicella Zoster Virus (VZV IgG)

Form number: **DM-F-02**Version number: **2.0**

Data Classification: Confidential

Bone Marrow Donor Programme 8 Sinaran Drive, #03-02 Novena Specialist Center, Singapore 307470 T: +65 69160370 F: +65 69160371

Effective Date: 23 Oct 2024

Page: 6 of 7



| VERSION | EFFECTIVE | DESCRIPTION OF CHANGE | PROCESS | OWNER(S) | APPROVED BY |
|---------|-------------|---|--|--|---|
| NUMBER | DATE | DESCRIPTION OF CHANGE | PREPARED BY | REVIEWED BY | APPROVED BY |
| | | Added "Weight Measurement Date" field under Patient Data. Added Contingency Plan Section, including Backup Donor Policy. Added Conditioning Regimen | Head of Donor Management Lee Shok Li | Head of Donor Management Lee Shok Li | Chief Executive Officer Charles Loh |
| 2.0 | 23 Oct 2024 | a. Added Conditioning Regimen explanation for clarity. 4. Added Appendix: Infectious Disease Markers. 5. Added into the Disclaimer: As per WMDA Standards 6.04.3 "HLA verification typing results of the potential recipient should be available prior to requesting a specific donor for workup. At the latest, results must be available before the donor begins mobilisation or proceeds to collection, or the patient begins with the preparative regimen, whichever is earliest." Please ensure the patient's confirmatory/verification typing result is available to the search registry for this donation request. | 16 Oct 2024 | 16 Oct 2024 | 22 Oct 2024 |

Form number: **DM-F-02**Version number: **2.0**

Data Classification: Confidential

Effective Date: 23 Oct 2024

Page: 7 of 7